Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 4Terminated 2Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 32Recurrence 8Neoplasms 6Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Smoldering Multiple Myeloma 1Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoma, Small Cell 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Melphalan 5Filgrastim 4birtamimab 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pomalidomide 2Calcium Dobesilate 2Bortezomib 2venetoclax 1pegfilgrastim 1nelarabine 1melflufen 1daratumumab 1Tetradecanoylphorbol Acetate 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Moxifloxacin 1Morphine 1Methadone 1Fluorescent Antibody Technique 1Fentanyl 1Diuretics 1Ciprofloxacin 1Blood Component Removal 1Amoxicillin-Potassium Clavulanate Combination 1Amifostine 14'-deoxy-4'-iododoxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Immunoglobulin Light-chain Amyloidosis × pomalidomide × Clear all
NCT04895917 2025-02-20

DarPAL

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Terminated
27 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01728259 2023-05-09

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
18 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡